| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.906 | 0.003 | 0.923 | Bronchodilator | 0.923 0.003 DBMET00386 0.87 0.003 DBMET02979 | DBMET00386 | |
| 0.816 | 0.001 | 0.816 | Adrenaline agonist | 0.786 0.001 DBMET00386 0.543 0.002 DBMET02979 | ||
| 0.809 | 0.001 | 0.809 | Beta adrenoreceptor agonist | 0.682 0.001 DBMET00386 0.436 0.002 DBMET02979 | ||
| 0.799 | 0.004 | 0.847 | Spasmolytic | 0.847 0.004 DBMET00386 0.749 0.005 DBMET02979 | DBMET00386 | |
| 0.784 | 0.001 | 0.784 | Beta 1 adrenoreceptor agonist | 0.444 0.001 DBMET00386 0.222 0.002 DBMET02979 | ||
| 0.727 | 0.003 | 0.823 | Anesthetic local | 0.823 0.002 DBMET00386 0.394 0.007 DBMET02979 | DBMET00386 | |
| 0.678 | 0.001 | 0.678 | Beta 2 adrenoreceptor agonist | 0.544 0.001 DBMET00386 0.303 0.001 DBMET02979 | ||
| 0.668 | 0.011 | 0.686 | Toll-Like receptor agonist | 0.686 0.01 DBMET00386 0.682 0.01 DBMET02979 | DBMET00386 | |
| 0.66 | 0.011 | 0.665 | Cholesterol antagonist | 0.626 0.015 DBMET00386 0.665 0.011 DBMET02979 | DBMET02979 | |
| 0.653 | 0.01 | 0.703 | Vasodilator, peripheral | 0.582 0.018 DBMET00386 0.703 0.006 DBMET02979 | DBMET02979 | |
| 0.653 | 0.012 | 0.676 | Toll-Like receptor 7 agonist | 0.676 0.01 DBMET00386 0.67 0.011 DBMET02979 | DBMET00386 | |
| 0.627 | 0.002 | 0.627 | Beta adrenoreceptor antagonist | 0.401 0.002 DBMET00386 0.26 0.003 DBMET02979 | ||
| 0.627 | 0.004 | 0.629 | Calcium channel L-type activator | 0.618 0.005 DBMET00386 0.629 0.004 DBMET02979 | DBMET02979 | |
| 0.597 | 0.001 | 0.597 | Beta 2 adrenoreceptor antagonist | 0.376 0.002 DBMET00386 0.242 0.003 DBMET02979 | ||
| 0.59 | 0.008 | 0.59 | Vasodilator, coronary | 0.54 0.011 DBMET00386 0.48 0.018 DBMET02979 | ||
| 0.601 | 0.02 | 0.67 | Antiobesity | 0.574 0.024 DBMET00386 0.67 0.013 DBMET02979 | DBMET02979 | |
| 0.596 | 0.028 | 0.688 | Cyclophilin D inhibitor | 0.575 0.032 DBMET00386 0.688 0.015 DBMET02979 | DBMET02979 | |
| 0.554 | 0.006 | 0.677 | Interleukin agonist | 0.47 0.011 DBMET00386 0.677 0.004 DBMET02979 | DBMET02979 | |
| 0.556 | 0.021 | 0.573 | Antithrombotic | 0.403 0.048 DBMET00386 0.573 0.019 DBMET02979 | DBMET02979 | |
| 0.562 | 0.036 | 0.57 | Transcription factor NF kappa B inhibitor | 0.565 0.036 DBMET00386 0.57 0.035 DBMET02979 | DBMET02979 | |
| 0.48 | 0.001 | 0.48 | Beta 3 adrenoreceptor agonist | 0.328 0.002 DBMET00386 0.204 0.002 DBMET02979 | ||
| 0.476 | 0.013 | 0.476 | Psychostimulant | 0.302 0.042 DBMET00386 0.447 0.016 DBMET02979 | ||
| 0.464 | 0.006 | 0.515 | Antiadrenergic | 0.515 0.005 DBMET00386 0.358 0.01 DBMET02979 | DBMET00386 | |
| 0.462 | 0.006 | 0.513 | Adrenaline antagonist | 0.513 0.005 DBMET00386 0.355 0.01 DBMET02979 | DBMET00386 | |
| 0.464 | 0.013 | 0.53 | Interleukin 2 agonist | 0.448 0.016 DBMET00386 0.53 0.005 DBMET02979 | DBMET02979 | |
| 0.46 | 0.009 | 0.46 | Calcium channel activator | 0.422 0.018 DBMET00386 0.45 0.011 DBMET02979 | ||
| 0.449 | 0.005 | 0.449 | Cholinergic antagonist | 0.44 0.006 DBMET00386 0.266 0.018 DBMET02979 | ||
| 0.447 | 0.004 | 0.463 | Acetylcholine muscarinic antagonist | 0.463 0.004 DBMET00386 0.262 0.013 DBMET02979 | DBMET00386 | |
| 0.447 | 0.005 | 0.447 | Acetylcholine antagonist | 0.437 0.006 DBMET00386 0.259 0.019 DBMET02979 | ||
| 0.438 | 0.002 | 0.438 | Beta 1 adrenoreceptor antagonist | 0.24 0.003 DBMET00386 0.192 0.004 DBMET02979 | ||
| 0.424 | 0.005 | 0.463 | Acetylcholine M1 receptor antagonist | 0.463 0.004 DBMET00386 0.292 0.016 DBMET02979 | DBMET00386 | |
| 0.41 | 0.003 | 0.418 | Acetylcholine M3 receptor antagonist | 0.418 0.003 DBMET00386 0.235 0.005 DBMET02979 | DBMET00386 | |
| 0.441 | 0.039 | 0.452 | Immunostimulant | 0.432 0.041 DBMET00386 0.452 0.036 DBMET02979 | DBMET02979 | |
| 0.392 | 0.007 | 0.451 | Insulin sensitizer | 0.322 0.012 DBMET00386 0.451 0.004 DBMET02979 | DBMET02979 | |
| 0.419 | 0.066 | 0.419 | Histamine release inhibitor | 0.281 0.134 DBMET00386 0.395 0.078 DBMET02979 | ||
| 0.344 | 0.008 | 0.344 | Phospholipase A2 inhibitor | 0.325 0.01 DBMET00386 0.29 0.015 DBMET02979 | ||
| 0.364 | 0.03 | 0.38 | Vasodilator | 0.38 0.027 DBMET00386 0.356 0.032 DBMET02979 | DBMET00386 | |
| 0.334 | 0.002 | 0.334 | Beta 3 adrenoreceptor antagonist | 0.233 0.004 DBMET00386 0.186 0.004 DBMET02979 | ||
| 0.392 | 0.066 | 0.41 | Immunosuppressant | 0.41 0.059 DBMET00386 0.368 0.078 DBMET02979 | DBMET00386 | |
| 0.332 | 0.015 | 0.336 | Phospholipase C inhibitor | 0.234 0.029 DBMET00386 0.336 0.015 DBMET02979 | DBMET02979 | |
| 0.351 | 0.035 | 0.39 | Hypolipemic | 0.39 0.027 DBMET00386 0.357 0.034 DBMET02979 | DBMET00386 | |
| 0.328 | 0.016 | 0.364 | Peptidyltransferase inhibitor | 0.338 0.014 DBMET00386 0.364 0.01 DBMET02979 | DBMET02979 | |
| 0.313 | 0.003 | 0.313 | Interferon agonist | 0.224 0.005 DBMET00386 0.232 0.005 DBMET02979 | ||
| 0.303 | 0.003 | 0.363 | Adenylate cyclase stimulant | 0.272 0.004 DBMET00386 0.363 0.002 DBMET02979 | DBMET02979 | |
| 0.308 | 0.013 | 0.351 | Adenylate cyclase inhibitor | 0.286 0.015 DBMET00386 0.351 0.009 DBMET02979 | DBMET02979 | |
| 0.336 | 0.041 | 0.39 | Hypoglycemic | 0.357 0.036 DBMET00386 0.39 0.029 DBMET02979 | DBMET02979 | |
| 0.32 | 0.042 | 0.35 | Angiogenesis stimulant | 0.29 0.053 DBMET00386 0.35 0.033 DBMET02979 | DBMET02979 | |
| 0.337 | 0.059 | 0.337 | 5 Hydroxytryptamine release stimulant | 0.193 0.127 DBMET00386 0.226 0.102 DBMET02979 | ||
| 0.322 | 0.049 | 0.333 | DNA damaging | 0.221 0.099 DBMET00386 0.333 0.046 DBMET02979 | DBMET02979 | |
| 0.322 | 0.054 | 0.35 | Antioxidant | 0.317 0.056 DBMET00386 0.35 0.046 DBMET02979 | DBMET02979 | |
| 0.316 | 0.05 | 0.325 | Cardiotonic | 0.325 0.047 DBMET00386 0.23 0.096 DBMET02979 | DBMET00386 | |
| 0.264 | 0.004 | 0.302 | Acetylcholine M5 receptor antagonist | 0.302 0.003 DBMET00386 0.103 0.017 DBMET02979 | DBMET00386 | |
| 0.278 | 0.02 | 0.278 | Monophenol monooxygenase inhibitor | 0.21 0.031 DBMET00386 0.246 0.025 DBMET02979 | ||
| 0.26 | 0.011 | 0.26 | Neurotrophic factor | 0.17 0.044 DBMET00386 0.142 0.066 DBMET02979 | ||
| 0.239 | 0.003 | 0.239 | Interferon inducer | 0.157 0.004 DBMET00386 0.142 0.005 DBMET02979 | ||
| 0.287 | 0.056 | 0.36 | Antiamyloidogenic | 0.36 0.037 DBMET00386 0.256 0.068 DBMET02979 | DBMET00386 | |
| 0.245 | 0.017 | 0.292 | Alkylator | 0.19 0.029 DBMET00386 0.292 0.013 DBMET02979 | DBMET02979 | |
| 0.222 | 0.009 | 0.413 | Mucolytic | 0.227 0.009 DBMET00386 0.413 0.003 DBMET02979 | DBMET02979 | |
| 0.224 | 0.015 | 0.237 | Toll-Like receptor 2 antagonist | 0.213 0.018 DBMET00386 0.237 0.012 DBMET02979 | DBMET02979 | |
| 0.263 | 0.054 | 0.34 | Amyloid beta aggregation inhibitor | 0.34 0.037 DBMET00386 0.199 0.078 DBMET02979 | DBMET00386 | |
| 0.251 | 0.043 | 0.335 | Growth hormone agonist | 0.136 0.1 DBMET00386 0.335 0.026 DBMET02979 | DBMET02979 | |
| 0.255 | 0.048 | 0.255 | Anesthetic general | 0.179 0.088 DBMET00386 0.242 0.054 DBMET02979 | ||
| 0.312 | 0.107 | 0.312 | Calpain 2 inhibitor | 0.272 0.133 DBMET00386 0.21 0.179 DBMET02979 | ||
| 0.216 | 0.017 | 0.461 | Expectorant | 0.229 0.015 DBMET00386 0.461 0.004 DBMET02979 | DBMET02979 | |
| 0.259 | 0.065 | 0.293 | Free radical scavenger | 0.247 0.07 DBMET00386 0.293 0.054 DBMET02979 | DBMET02979 | |
| 0.226 | 0.033 | 0.251 | Protein kinase stimulant | 0.205 0.04 DBMET00386 0.251 0.026 DBMET02979 | DBMET02979 | |
| 0.198 | 0.007 | 0.254 | Acetylcholine M2 receptor antagonist | 0.254 0.005 DBMET00386 0.074 0.033 DBMET02979 | DBMET00386 | |
| 0.283 | 0.095 | 0.355 | Sodium/bile acid cotransporter inhibitor | 0.214 0.169 DBMET00386 0.355 0.037 DBMET02979 | DBMET02979 | |
| 0.222 | 0.034 | 0.222 | Melanin inhibitor | 0.17 0.059 DBMET00386 0.22 0.034 DBMET02979 | ||
| 0.257 | 0.07 | 0.382 | Platelet antagonist | 0.239 0.077 DBMET00386 0.382 0.031 DBMET02979 | DBMET02979 | |
| 0.197 | 0.013 | 0.197 | Photosensitizer | 0.138 0.039 DBMET00386 0.19 0.015 DBMET02979 | ||
| 0.179 | 0.006 | 0.206 | Ornithine decarboxylase inhibitor | 0.206 0.005 DBMET00386 0.199 0.005 DBMET02979 | DBMET00386 | |
| 0.187 | 0.016 | 0.187 | Vanilloid 1 agonist | 0.142 0.047 DBMET00386 0.164 0.027 DBMET02979 | ||
| 0.183 | 0.013 | 0.208 | Sphingomyelinase inhibitor | 0.208 0.008 DBMET00386 0.09 0.071 DBMET02979 | DBMET00386 | |
| 0.181 | 0.013 | 0.23 | Aminoacyl-tRNA synthetase inhibitor | 0.181 0.013 DBMET00386 0.23 0.009 DBMET02979 | DBMET02979 | |
| 0.241 | 0.073 | 0.365 | DNA synthesis inhibitor | 0.234 0.079 DBMET00386 0.365 0.027 DBMET02979 | DBMET02979 | |
| 0.208 | 0.042 | 0.26 | Amylase inhibitor | 0.206 0.042 DBMET00386 0.26 0.025 DBMET02979 | DBMET02979 | |
| 0.179 | 0.016 | 0.179 | Sphingosine 1-phosphate receptor 2 antagonist | 0.168 0.023 DBMET00386 0.162 0.027 DBMET02979 | ||
| 0.187 | 0.027 | 0.257 | Interleukin 4 antagonist | 0.257 0.012 DBMET00386 0.173 0.033 DBMET02979 | DBMET00386 | |
| 0.168 | 0.008 | 0.168 | Leukotriene antagonist | 0.149 0.01 DBMET00386 0.144 0.011 DBMET02979 | ||
| 0.168 | 0.01 | 0.186 | Toll-Like receptor 3 antagonist | 0.186 0.008 DBMET00386 0.105 0.044 DBMET02979 | DBMET00386 | |
| 0.177 | 0.023 | 0.208 | Carbonic anhydrase XV inhibitor | 0.208 0.017 DBMET00386 0.142 0.034 DBMET02979 | DBMET00386 | |
| 0.265 | 0.113 | 0.358 | Apoptosis antagonist | 0.213 0.163 DBMET00386 0.358 0.052 DBMET02979 | DBMET02979 | |
| 0.156 | 0.004 | 0.156 | Glucosylceramidase inhibitor | 0.122 0.005 DBMET00386 0.062 0.029 DBMET02979 | ||
| 0.162 | 0.013 | 0.178 | Anabolic | 0.152 0.017 DBMET00386 0.178 0.008 DBMET02979 | DBMET02979 | |
| 0.212 | 0.066 | 0.212 | Neurotrophic factor enhancer | 0.206 0.071 DBMET02979 | ||
| 0.155 | 0.011 | 0.257 | Phenylalanine 4-hydroxylase inhibitor | 0.112 0.021 DBMET00386 0.257 0.005 DBMET02979 | DBMET02979 | |
| 0.164 | 0.021 | 0.189 | Gastric antisecretory | 0.189 0.014 DBMET00386 0.13 0.037 DBMET02979 | DBMET00386 | |
| 0.172 | 0.032 | 0.172 | Antibacterial (Helicobacter pylori) | 0.169 0.034 DBMET00386 0.142 0.053 DBMET02979 | ||
| 0.187 | 0.047 | 0.191 | Lipid peroxidase inhibitor | 0.146 0.071 DBMET00386 0.191 0.045 DBMET02979 | DBMET02979 | |
| 0.139 | 0.005 | 0.139 | Oleamide hydrolase inhibitor | 0.077 0.013 DBMET00386 | ||
| 0.211 | 0.078 | 0.29 | Interleukin antagonist | 0.249 0.062 DBMET00386 0.29 0.05 DBMET02979 | DBMET02979 | |
| 0.311 | 0.182 | 0.424 | Caspase 9 stimulant | 0.291 0.204 DBMET00386 0.424 0.097 DBMET02979 | DBMET02979 | |
| 0.164 | 0.037 | 0.164 | Cyclooxygenase 3 inhibitor | 0.15 0.048 DBMET00386 0.158 0.042 DBMET02979 | ||
| 0.148 | 0.022 | 0.206 | Electron transport complex I inhibitor | 0.206 0.008 DBMET00386 0.114 0.056 DBMET02979 | DBMET00386 | |
| 0.218 | 0.096 | 0.218 | Calpain inhibitor | 0.17 0.148 DBMET02979 | ||
| 0.155 | 0.034 | 0.189 | Chelator | 0.142 0.039 DBMET00386 0.189 0.027 DBMET02979 | DBMET02979 | |
| 0.19 | 0.071 | 0.198 | P-glycoprotein inhibitor | 0.198 0.065 DBMET00386 0.141 0.131 DBMET02979 | DBMET00386 | |
| 0.113 | 0.005 | 0.125 | Mannosidase inhibitor | 0.125 0.004 DBMET00386 0.111 0.005 DBMET02979 | DBMET00386 | |
| 0.152 | 0.043 | 0.175 | Cholesterol synthesis inhibitor | 0.097 0.091 DBMET00386 0.175 0.034 DBMET02979 | DBMET02979 | |
| 0.181 | 0.076 | 0.199 | Nitric oxide antagonist | 0.194 0.069 DBMET00386 0.199 0.068 DBMET02979 | DBMET02979 | |
| 0.139 | 0.034 | 0.168 | Mediator release inhibitor | 0.168 0.022 DBMET00386 0.147 0.03 DBMET02979 | DBMET00386 | |
| 0.287 | 0.182 | 0.287 | Apoptosis agonist | 0.274 0.192 DBMET00386 0.281 0.186 DBMET02979 | ||
| 0.152 | 0.048 | 0.154 | DNA polymerase I inhibitor | 0.154 0.047 DBMET02979 | DBMET02979 | |
| 0.109 | 0.006 | 0.109 | Sphingosine kinase 2 inhibitor | 0.059 0.033 DBMET00386 | ||
| 0.219 | 0.119 | 0.389 | 5 Hydroxytryptamine uptake stimulant | 0.204 0.145 DBMET00386 0.389 0.016 DBMET02979 | DBMET02979 | |
| 0.106 | 0.007 | 0.106 | Sphingosine 1-phosphate receptor 3 antagonist | 0.09 0.011 DBMET00386 0.068 0.027 DBMET02979 | ||
| 0.111 | 0.013 | 0.124 | Maillard reaction inhibitor | 0.124 0.009 DBMET00386 0.123 0.01 DBMET02979 | DBMET00386 | |
| 0.107 | 0.009 | 0.107 | Leukotriene B4 antagonist | 0.095 0.011 DBMET00386 0.09 0.013 DBMET02979 | ||
| 0.103 | 0.006 | 0.103 | Alpha-mannosidase inhibitor | 0.103 0.006 DBMET00386 0.096 0.007 DBMET02979 | ||
| 0.103 | 0.007 | 0.103 | Sphingosine kinase inhibitor | 0.057 0.044 DBMET00386 | ||
| 0.116 | 0.026 | 0.17 | Interleukin 5 antagonist | 0.17 0.008 DBMET00386 0.101 0.04 DBMET02979 | DBMET00386 | |
| 0.17 | 0.081 | 0.227 | Succinate dehydrogenase inhibitor | 0.195 0.053 DBMET00386 0.227 0.032 DBMET02979 | DBMET02979 | |
| 0.11 | 0.028 | 0.11 | Somatostatin 1 agonist | 0.089 0.042 DBMET00386 0.1 0.034 DBMET02979 | ||
| 0.142 | 0.062 | 0.146 | Farnesoid X receptor antagonist | 0.146 0.057 DBMET00386 0.145 0.059 DBMET02979 | DBMET00386 | |
| 0.116 | 0.037 | 0.116 | Calcium antagonist | |||
| 0.125 | 0.047 | 0.157 | Nav1.4 sodium channel blocker | 0.106 0.068 DBMET00386 0.157 0.031 DBMET02979 | DBMET02979 | |
| 0.105 | 0.03 | 0.105 | Histamine H2 receptor antagonist | |||
| 0.249 | 0.178 | 0.312 | Antibacterial | 0.265 0.163 DBMET00386 0.312 0.127 DBMET02979 | DBMET02979 | |
| 0.079 | 0.01 | 0.096 | Adenine nucleotide translocase inhibitor | 0.083 0.008 DBMET00386 0.096 0.005 DBMET02979 | DBMET02979 | |
| 0.096 | 0.027 | 0.118 | Sphingosine 1-phosphate receptor 4 agonist | 0.118 0.017 DBMET02979 | DBMET02979 | |
| 0.085 | 0.017 | 0.088 | Thromboxane antagonist | 0.056 0.036 DBMET00386 0.088 0.016 DBMET02979 | DBMET02979 | |
| 0.081 | 0.014 | 0.084 | Thromboxane A2 antagonist | 0.059 0.029 DBMET00386 0.084 0.013 DBMET02979 | DBMET02979 | |
| 0.08 | 0.014 | 0.094 | Sphingosine 1-phosphate receptor 1 antagonist | 0.064 0.024 DBMET00386 0.094 0.01 DBMET02979 | DBMET02979 | |
| 0.072 | 0.006 | 0.072 | Cytokine production stimulant | 0.059 0.014 DBMET00386 0.045 0.043 DBMET02979 | ||
| 0.113 | 0.049 | 0.172 | Carbonic anhydrase III inhibitor | 0.141 0.032 DBMET00386 0.172 0.022 DBMET02979 | DBMET02979 | |
| 0.099 | 0.035 | 0.099 | Vanilloid agonist | 0.086 0.054 DBMET02979 | ||
| 0.123 | 0.063 | 0.123 | Proteasome inhibitor | 0.103 0.084 DBMET02979 | ||
| 0.139 | 0.082 | 0.194 | Hemostatic | 0.194 0.035 DBMET02979 | DBMET02979 | |
| 0.06 | 0.004 | 0.06 | Ceramide glucosyltransferase inhibitor | 0.058 0.004 DBMET00386 0.044 0.012 DBMET02979 | ||
| 0.09 | 0.034 | 0.09 | Lipase inhibitor | |||
| 0.07 | 0.014 | 0.071 | Lysophosphatidic acid 3 receptor antagonist | 0.061 0.021 DBMET00386 0.071 0.014 DBMET02979 | DBMET02979 | |
| 0.064 | 0.008 | 0.064 | Sphingosine kinase 1 inhibitor | |||
| 0.109 | 0.054 | 0.109 | Butyrylcholinesterase inhibitor | 0.092 0.069 DBMET00386 | ||
| 0.069 | 0.015 | 0.069 | Leukotriene C antagonist | 0.064 0.021 DBMET00386 0.064 0.021 DBMET02979 | ||
| 0.142 | 0.089 | 0.164 | Interferon gamma antagonist | 0.138 0.095 DBMET00386 0.164 0.062 DBMET02979 | DBMET02979 | |
| 0.079 | 0.027 | 0.131 | Prostaglandin EP2 antagonist | 0.099 0.019 DBMET00386 0.131 0.012 DBMET02979 | DBMET02979 | |
| 0.094 | 0.043 | 0.122 | Glutathione S-transferase inhibitor | 0.081 0.059 DBMET00386 0.122 0.022 DBMET02979 | DBMET02979 | |
| 0.195 | 0.146 | 0.195 | Lipoxygenase inhibitor | 0.195 0.145 DBMET00386 0.189 0.152 DBMET02979 | ||
| 0.127 | 0.079 | 0.149 | Bone formation stimulant | 0.149 0.06 DBMET00386 0.138 0.069 DBMET02979 | DBMET00386 | |
| 0.06 | 0.013 | 0.066 | Sphingosine 1-phosphate receptor 1 agonist | 0.066 0.01 DBMET02979 | DBMET02979 | |
| 0.178 | 0.132 | 0.221 | Nitric-oxide synthase stimulant | 0.186 0.116 DBMET00386 0.221 0.059 DBMET02979 | DBMET02979 | |
| 0.066 | 0.021 | 0.066 | Epithelial sodium channel blocker | |||
| 0.152 | 0.108 | 0.2 | Hepatoprotectant | 0.138 0.123 DBMET00386 0.2 0.065 DBMET02979 | DBMET02979 | |
| 0.061 | 0.016 | 0.071 | Sphingosine 1-phosphate receptor agonist | 0.071 0.011 DBMET02979 | DBMET02979 | |
| 0.11 | 0.066 | 0.11 | Acetylcholine release stimulant | |||
| 0.081 | 0.037 | 0.081 | Amidase inhibitor | |||
| 0.068 | 0.025 | 0.076 | NMDA 2A receptor antagonist | 0.076 0.021 DBMET02979 | DBMET02979 | |
| 0.098 | 0.056 | 0.098 | Phosphodiesterase 6D inhibitor | |||
| 0.118 | 0.076 | 0.118 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.083 | 0.04 | 0.088 | Sphingosine 1-phosphate receptor antagonist | 0.088 0.033 DBMET02979 | DBMET02979 | |
| 0.046 | 0.004 | 0.046 | Acid ceramidase inhibitor | 0.028 0.013 DBMET00386 | ||
| 0.118 | 0.076 | 0.118 | Nav1.3 sodium channel blocker | 0.115 0.079 DBMET00386 | ||
| 0.072 | 0.03 | 0.077 | Nitric oxide donor | 0.077 0.025 DBMET00386 | DBMET00386 | |
| 0.052 | 0.01 | 0.065 | Prostaglandin agonist | 0.049 0.01 DBMET00386 0.065 0.008 DBMET02979 | DBMET02979 | |
| 0.091 | 0.05 | 0.105 | Transcription factor NF kappa B stimulant | 0.089 0.052 DBMET00386 0.105 0.035 DBMET02979 | DBMET02979 | |
| 0.135 | 0.095 | 0.19 | Thrombolytic | 0.19 0.057 DBMET02979 | DBMET02979 | |
| 0.196 | 0.156 | 0.315 | Hypoxia-inducible factor 1 alpha inhibitor | 0.247 0.103 DBMET00386 0.315 0.059 DBMET02979 | DBMET02979 | |
| 0.152 | 0.112 | 0.208 | Non-steroidal antiinflammatory agent | 0.2 0.071 DBMET00386 0.208 0.065 DBMET02979 | DBMET02979 | |
| 0.121 | 0.082 | 0.121 | Nav1.2 sodium channel blocker | |||
| 0.047 | 0.009 | 0.066 | Lysophosphatidic acid 2 receptor antagonist | 0.066 0.006 DBMET00386 0.033 0.018 DBMET02979 | DBMET00386 | |
| 0.081 | 0.043 | 0.145 | Cathepsin G inhibitor | 0.145 0.022 DBMET02979 | DBMET02979 | |
| 0.047 | 0.009 | 0.069 | Prostaglandin D2 agonist | 0.069 0.004 DBMET00386 0.056 0.006 DBMET02979 | DBMET00386 | |
| 0.045 | 0.007 | 0.045 | Sodium/glucose cotransporter 2 inhibitor | 0.028 0.016 DBMET00386 | ||
| 0.08 | 0.044 | 0.288 | Glutamate decarboxylase inhibitor | 0.084 0.041 DBMET00386 0.288 0.004 DBMET02979 | DBMET02979 | |
| 0.1 | 0.065 | 0.135 | Aminopeptidase B inhibitor | 0.135 0.045 DBMET02979 | DBMET02979 | |
| 0.044 | 0.009 | 0.053 | Leukotriene B4 receptor 1 antagonist | 0.053 0.006 DBMET00386 0.042 0.011 DBMET02979 | DBMET00386 | |
| 0.046 | 0.014 | 0.046 | Leukotriene C4 antagonist | 0.042 0.02 DBMET00386 0.042 0.02 DBMET02979 | ||
| 0.041 | 0.009 | 0.041 | Calcium-independent phospholipase A2 inhibitor | 0.032 0.031 DBMET00386 | ||
| 0.039 | 0.007 | 0.039 | Sodium/glucose cotransporter inhibitor | 0.025 0.018 DBMET00386 | ||
| 0.056 | 0.024 | 0.056 | Adenosine deaminase inhibitor | |||
| 0.094 | 0.063 | 0.113 | Bile acid receptor antagonist | 0.113 0.027 DBMET02979 | DBMET02979 | |
| 0.073 | 0.042 | 0.079 | Leukotriene synthesis inhibitor | 0.072 0.043 DBMET00386 0.079 0.038 DBMET02979 | DBMET02979 | |
| 0.054 | 0.024 | 0.067 | Dopamine D2 agonist | 0.067 0.018 DBMET00386 | DBMET00386 | |
| 0.038 | 0.009 | 0.051 | Prostaglandin EP2 agonist | 0.039 0.009 DBMET00386 0.051 0.005 DBMET02979 | DBMET02979 | |
| 0.036 | 0.007 | 0.036 | Lysophosphatidic acid receptor 1 agonist | 0.026 0.016 DBMET00386 0.026 0.016 DBMET02979 | ||
| 0.039 | 0.011 | 0.073 | Prostaglandin EP4 antagonist | 0.029 0.016 DBMET00386 0.073 0.005 DBMET02979 | DBMET02979 | |
| 0.072 | 0.044 | 0.14 | Alpha adrenoreceptor agonist | 0.14 0.018 DBMET00386 | DBMET00386 | |
| 0.047 | 0.02 | 0.047 | Plasmepsin II inhibitor | |||
| 0.045 | 0.019 | 0.045 | Sphingosine 1-phosphate receptor 3 agonist | 0.035 0.024 DBMET02979 | ||
| 0.073 | 0.048 | 0.263 | Histidine decarboxylase inhibitor | 0.075 0.046 DBMET00386 0.263 0.008 DBMET02979 | DBMET02979 | |
| 0.174 | 0.149 | 0.238 | Superoxide dismutase inhibitor | 0.176 0.147 DBMET00386 0.238 0.083 DBMET02979 | DBMET02979 | |
| 0.057 | 0.032 | 0.067 | Thromboxane synthase inhibitor | 0.067 0.019 DBMET02979 | DBMET02979 | |
| 0.08 | 0.057 | 0.126 | Carbonic anhydrase VI inhibitor | 0.098 0.041 DBMET00386 0.126 0.027 DBMET02979 | DBMET02979 | |
| 0.069 | 0.045 | 0.079 | Dopamine agonist | 0.079 0.037 DBMET00386 | DBMET00386 | |
| 0.046 | 0.022 | 0.046 | Dopamine D3 agonist | 0.042 0.025 DBMET00386 | ||
| 0.051 | 0.028 | 0.051 | Cholesterol esterase inhibitor | |||
| 0.095 | 0.072 | 0.095 | Nav1.1 sodium channel blocker | |||
| 0.032 | 0.01 | 0.032 | 1,3-Beta-glucan synthase inhibitor | 0.032 0.011 DBMET00386 0.031 0.012 DBMET02979 | ||
| 0.159 | 0.137 | 0.159 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.055 | 0.034 | 0.079 | Sphingosine 1-phosphate receptor 5 agonist | 0.079 0.013 DBMET02979 | DBMET02979 | |
| 0.066 | 0.045 | 0.084 | Selectin antagonist | 0.084 0.034 DBMET02979 | DBMET02979 | |
| 0.09 | 0.072 | 0.106 | Interleukin 12 antagonist | 0.106 0.045 DBMET02979 | DBMET02979 | |
| 0.053 | 0.034 | 0.053 | Vanilloid 2 antagonist | |||
| 0.064 | 0.045 | 0.067 | Neuraminidase (influenza) inhibitor | 0.067 0.039 DBMET00386 0.063 0.047 DBMET02979 | DBMET00386 | |
| 0.105 | 0.087 | 0.105 | Estrogen antagonist | 0.101 0.095 DBMET00386 | ||
| 0.024 | 0.007 | 0.024 | Calcium-sensing receptor antagonist | 0.023 0.007 DBMET00386 0.019 0.009 DBMET02979 | ||
| 0.153 | 0.135 | 0.153 | Growth factor agonist | 0.152 0.137 DBMET02979 | ||
| 0.028 | 0.012 | 0.041 | Prostaglandin E2 agonist | 0.027 0.013 DBMET00386 0.041 0.007 DBMET02979 | DBMET02979 | |
| 0.095 | 0.079 | 0.095 | Toll-Like receptor 4 antagonist | 0.09 0.089 DBMET02979 | ||
| 0.073 | 0.058 | 0.089 | Topoisomerase II alpha inhibitor | 0.067 0.065 DBMET00386 0.089 0.047 DBMET02979 | DBMET02979 | |
| 0.037 | 0.022 | 0.055 | Phosphoglycerate kinase inhibitor | 0.037 0.023 DBMET00386 0.055 0.012 DBMET02979 | DBMET02979 | |
| 0.13 | 0.117 | 0.13 | CF transmembrane conductance regulator agonist | |||
| 0.025 | 0.013 | 0.028 | Prostaglandin F2 alpha agonist | 0.028 0.01 DBMET02979 | DBMET02979 | |
| 0.074 | 0.062 | 0.074 | Acetylcholine nicotinic antagonist | |||
| 0.02 | 0.009 | 0.029 | Ileal bile acid transport inhibitor | 0.029 0.005 DBMET02979 | DBMET02979 | |
| 0.044 | 0.036 | 0.062 | Antimetabolite | 0.062 0.025 DBMET02979 | DBMET02979 | |
| 0.012 | 0.006 | 0.022 | Thromboxane agonist | 0.012 0.006 DBMET00386 0.022 0.004 DBMET02979 | DBMET02979 | |
| 0.097 | 0.091 | 0.097 | Nav1.5 sodium channel blocker | |||
| 0.047 | 0.041 | 0.049 | Squalene epoxidase inhibitor | 0.049 0.035 DBMET00386 | DBMET00386 | |
| 0.07 | 0.065 | 0.073 | Keratolytic | 0.073 0.059 DBMET02979 | DBMET02979 | |
| 0.061 | 0.056 | 0.226 | Phosphofructokinase-1 inhibitor | 0.069 0.048 DBMET00386 0.226 0.009 DBMET02979 | DBMET02979 | |
| 0.02 | 0.016 | 0.02 | Lysophosphatidic acid 1 receptor antagonist | 0.02 0.017 DBMET00386 | ||
| 0.021 | 0.017 | 0.021 | Leukotriene B4 receptor 2 antagonist | 0.02 0.018 DBMET02979 | ||
| 0.034 | 0.03 | 0.034 | Somatostatin 1 antagonist | |||
| 0.185 | 0.181 | 0.237 | Insulysin inhibitor | 0.237 0.109 DBMET02979 | DBMET02979 | |
| 0.024 | 0.021 | 0.031 | Thyroid hormone agonist | 0.031 0.011 DBMET02979 | DBMET02979 | |
| 0.03 | 0.027 | 0.03 | Melatonin 2 agonist | |||
| 0.024 | 0.02 | 0.024 | Leukotriene D4 antagonist | 0.023 0.022 DBMET02979 | ||
| 0.077 | 0.076 | 0.083 | Estrogen-related receptor beta agonist | 0.083 0.056 DBMET02979 | DBMET02979 | |
| 0.034 | 0.035 | 0.059 | Toll-Like receptor 2 agonist | 0.039 0.031 DBMET00386 0.059 0.02 DBMET02979 | DBMET02979 | |
| 0.019 | 0.02 | 0.022 | Alpha 1a adrenoreceptor agonist | 0.022 0.016 DBMET00386 0.02 0.018 DBMET02979 | DBMET00386 | |
| 0.069 | 0.071 | 0.1 | GABA B receptor agonist | 0.1 0.017 DBMET02979 | DBMET02979 | |
| 0.078 | 0.08 | 0.145 | HIV-1 integrase (Overall Integration) inhibitor | 0.145 0.027 DBMET02979 | DBMET02979 | |
| 0.044 | 0.047 | 0.059 | Ribonucleotide reductase inhibitor | 0.059 0.037 DBMET02979 | DBMET02979 | |
| 0.052 | 0.055 | 0.054 | Neuraminidase inhibitor | 0.054 0.052 DBMET00386 | DBMET00386 | |
| 0.043 | 0.047 | 0.055 | Ribonucleoside-diphosphate reductase inhibitor | 0.055 0.037 DBMET02979 | DBMET02979 | |
| 0.014 | 0.019 | 0.017 | Vitamin D receptor agonist | 0.017 0.011 DBMET02979 | DBMET02979 | |
| 0.016 | 0.023 | 0.018 | Antibiotic Anthracycline-like | 0.018 0.016 DBMET02979 | DBMET02979 | |
| 0.009 | 0.017 | 0.015 | Prostaglandin EP4 agonist | 0.015 0.01 DBMET02979 | DBMET02979 | |
| 0.135 | 0.145 | 0.161 | Neurotensin receptor agonist | 0.161 0.077 DBMET02979 | DBMET02979 | |
| 0.085 | 0.096 | 0.108 | Protein-tyrosine phosphatase 1B inhibitor | 0.108 0.071 DBMET02979 | DBMET02979 | |
| 0.103 | 0.115 | 0.144 | Histone deacetylase SIRT1 inhibitor | 0.144 0.067 DBMET02979 | DBMET02979 | |
| 0.018 | 0.031 | 0.021 | Vitamin D receptor antagonist | 0.021 0.018 DBMET00386 | DBMET00386 | |
| 0.175 | 0.188 | 0.244 | Tyrosine 3 hydroxylase inhibitor | 0.244 0.074 DBMET02979 | DBMET02979 | |
| 0.111 | 0.125 | 0.148 | Protein-tyrosine phosphatase inhibitor | 0.148 0.081 DBMET02979 | DBMET02979 | |
| 0.069 | 0.082 | 0.094 | NMDA receptor antagonist | 0.094 0.051 DBMET02979 | DBMET02979 | |
| 0.104 | 0.119 | 0.163 | Peroxidase inhibitor | 0.163 0.072 DBMET02979 | DBMET02979 | |
| 0.009 | 0.024 | 0.015 | Prostacyclin agonist | 0.015 0.012 DBMET02979 | DBMET02979 | |
| 0.054 | 0.07 | 0.072 | NMDA 2 receptor antagonist | 0.072 0.049 DBMET02979 | DBMET02979 | |
| 0.033 | 0.048 | 0.056 | Glycine transporter 2 inhibitor | 0.056 0.027 DBMET02979 | DBMET02979 | |
| 0.084 | 0.102 | 0.176 | Adenylate kinase inhibitor | 0.095 0.075 DBMET00386 0.176 0.019 DBMET02979 | DBMET02979 | |
| 0.059 | 0.081 | 0.068 | CDC25A inhibitor | 0.068 0.06 DBMET02979 | DBMET02979 | |
| 0.044 | 0.067 | 0.091 | Carbonic anhydrase stimulant | 0.091 0.021 DBMET02979 | DBMET02979 | |
| 0.074 | 0.097 | 0.101 | Hematopoietic | 0.101 0.034 DBMET02979 | DBMET02979 | |
| 0.042 | 0.065 | 0.048 | Factor III inhibitor | 0.048 0.041 DBMET02979 | DBMET02979 | |
| 0.179 | 0.205 | 0.213 | Caspase 3 stimulant | 0.213 0.151 DBMET02979 | DBMET02979 | |
| 0.074 | 0.099 | 0.087 | Alpha 2c adrenoreceptor antagonist | 0.087 0.079 DBMET00386 | DBMET00386 | |
| 0.017 | 0.042 | 0.082 | Glucagon receptor antagonist | 0.082 0.005 DBMET02979 | DBMET02979 | |
| 0.071 | 0.098 | 0.201 | Triose-phosphate isomerase inhibitor | 0.201 0.011 DBMET02979 | DBMET02979 | |
| 0.054 | 0.081 | 0.073 | Acetylcholine M4 receptor antagonist | 0.073 0.054 DBMET00386 | DBMET00386 | |
| 0.048 | 0.075 | 0.085 | Prostaglandin F2 alpha antagonist | 0.085 0.019 DBMET02979 | DBMET02979 | |
| 0.053 | 0.08 | 0.079 | Na+ K+ transporting ATPase inhibitor | 0.079 0.052 DBMET02979 | DBMET02979 | |
| 0.118 | 0.147 | 0.187 | Platelet adhesion inhibitor | 0.187 0.078 DBMET00386 0.156 0.099 DBMET02979 | DBMET00386 | |
| 0.052 | 0.082 | 0.075 | Carbonic anhydrase XIII inhibitor | 0.075 0.054 DBMET02979 | DBMET02979 | |
| 0.085 | 0.116 | 0.103 | Factor V inhibitor | 0.103 0.062 DBMET02979 | DBMET02979 | |
| 0.026 | 0.057 | 0.038 | Erythropoietin receptor agonist | 0.038 0.03 DBMET02979 | DBMET02979 | |
| 0.058 | 0.093 | 0.066 | Peroxisome proliferator-activated receptor gamma antagonist | 0.066 0.064 DBMET02979 | DBMET02979 | |
| 0.032 | 0.069 | 0.049 | Carbonic anhydrase XIV inhibitor | 0.049 0.033 DBMET02979 | DBMET02979 | |
| 0.02 | 0.057 | 0.039 | Complement C3a chemotactic receptor antagonist | 0.039 0.033 DBMET02979 | DBMET02979 | |
| 0.048 | 0.088 | 0.067 | Sirtuin 1 inhibitor | 0.067 0.048 DBMET02979 | DBMET02979 | |
| 0.085 | 0.13 | 0.156 | Aldehyde dehydrogenase inhibitor | 0.156 0.044 DBMET02979 | DBMET02979 | |
| 0.024 | 0.073 | 0.052 | Membrane dipeptidase inhibitor | 0.052 0.014 DBMET02979 | DBMET02979 | |
| 0.064 | 0.112 | 0.096 | Topoisomerase I inhibitor | 0.096 0.073 DBMET00386 0.086 0.083 DBMET02979 | DBMET00386 | |
| 0.024 | 0.075 | 0.054 | Phosphorylase inhibitor | 0.054 0.028 DBMET02979 | DBMET02979 | |
| 0.026 | 0.08 | 0.068 | Ornithine carbamoyltransferase inhibitor | 0.068 0.026 DBMET02979 | DBMET02979 | |
| 0.039 | 0.094 | 0.061 | Carbonic anhydrase V inhibitor | 0.061 0.052 DBMET02979 | DBMET02979 | |
| 0.046 | 0.104 | 0.074 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.074 0.056 DBMET02979 | DBMET02979 | |
| 0.041 | 0.104 | 0.062 | Carbonic anhydrase VA inhibitor | 0.062 0.056 DBMET02979 | DBMET02979 | |
| 0.134 | 0.198 | 0.238 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.238 0.048 DBMET02979 | DBMET02979 | |
| 0.064 | 0.134 | 0.093 | Thioredoxin inhibitor | 0.093 0.057 DBMET02979 | DBMET02979 | |
| 0.04 | 0.111 | 0.278 | Porphobilinogen synthase inhibitor | 0.278 0.006 DBMET02979 | DBMET02979 | |
| 0.038 | 0.113 | 0.062 | Purinergic P2X1 antagonist | 0.062 0.04 DBMET02979 | DBMET02979 | |
| 0.043 | 0.117 | 0.076 | Aminopeptidase I inhibitor | 0.076 0.046 DBMET02979 | DBMET02979 | |
| 0.068 | 0.144 | 0.111 | Histone deacetylase class III inhibitor | 0.111 0.078 DBMET02979 | DBMET02979 | |
| 0.028 | 0.106 | 0.054 | Alpha 1 adrenoreceptor agonist | 0.054 0.044 DBMET00386 | DBMET00386 | |
| 0.094 | 0.176 | 0.176 | Insulin secretagoues | 0.176 0.051 DBMET02979 | DBMET02979 | |
| 0.008 | 0.092 | 0.034 | Arginase inhibitor | 0.034 0.028 DBMET02979 | DBMET02979 | |
| 0.058 | 0.146 | 0.123 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.123 0.037 DBMET02979 | DBMET02979 | |
| 0.028 | 0.12 | 0.064 | Glucose-6-phosphate isomerase inhibitor | 0.064 0.016 DBMET02979 | DBMET02979 | |
| 0.054 | 0.148 | 0.106 | Prolactin inhibitor | 0.106 0.049 DBMET02979 | DBMET02979 | |
| 0.069 | 0.168 | 0.212 | Alpha-N-acetylglucosaminidase inhibitor | 0.212 0.031 DBMET02979 | DBMET02979 | |
| 0.009 | 0.11 | 0.026 | Lysine carboxypeptidase inhibitor | 0.026 0.02 DBMET02979 | DBMET02979 | |
| 0.099 | 0.202 | 0.136 | Interleukin 6 antagonist | 0.136 0.113 DBMET00386 0.131 0.122 DBMET02979 | DBMET00386 | |
| 0.083 | 0.201 | 0.154 | Arachidonic acid antagonist | 0.154 0.084 DBMET02979 | DBMET02979 | |
| 0.114 | 0.235 | 0.144 | Ca2+-transporting ATPase inhibitor | 0.144 0.058 DBMET02979 | DBMET02979 | |
| 0.02 | 0.147 | 0.05 | Acyl-CoA dehydrogenase inhibitor | 0.05 0.042 DBMET02979 | DBMET02979 | |
| 0.202 | 0.331 | 0.279 | Antiinflammatory | 0.279 0.236 DBMET00386 | DBMET00386 | |
| 0.062 | 0.192 | 0.107 | Glutamate release inhibitor | 0.107 0.033 DBMET02979 | DBMET02979 | |
| 0.059 | 0.19 | 0.114 | Caspase 3 inhibitor | 0.114 0.069 DBMET02979 | DBMET02979 | |
| 0.042 | 0.178 | 0.082 | Alcohol dehydrogenase inhibitor | 0.082 0.076 DBMET02979 | DBMET02979 | |
| 0.098 | 0.238 | 0.141 | Lipocortins synthesis antagonist | 0.141 0.119 DBMET02979 | DBMET02979 | |
| 0.047 | 0.187 | 0.075 | Vanilloid 4 agonist | 0.075 0.05 DBMET02979 | DBMET02979 | |
| 0.016 | 0.159 | 0.058 | NMDA 2C receptor antagonist | 0.058 0.047 DBMET02979 | DBMET02979 | |
| 0.074 | 0.219 | 0.181 | Cell wall synthesis inhibitor | 0.181 0.039 DBMET02979 | DBMET02979 | |
| 0.03 | 0.175 | 0.048 | CD45 antagonist | 0.048 0.04 DBMET02979 | DBMET02979 | |
| 0.05 | 0.203 | 0.095 | NADH dehydrogenase inhibitor | 0.095 0.05 DBMET02979 | DBMET02979 | |
| 0.035 | 0.2 | 0.134 | Glutamate dehydrogenase inhibitor | 0.134 0.019 DBMET02979 | DBMET02979 | |
| 0.028 | 0.197 | 0.092 | NMDA receptor agonist | 0.092 0.023 DBMET02979 | DBMET02979 | |
| 0.112 | 0.29 | 0.201 | Gastrin inhibitor | 0.201 0.148 DBMET02979 | DBMET02979 | |
| 0.044 | 0.229 | 0.091 | Interleukin 1 beta converting enzyme inhibitor | 0.091 0.071 DBMET02979 | DBMET02979 | |
| 0.06 | 0.258 | 0.112 | Folate antagonist | 0.112 0.047 DBMET02979 | DBMET02979 | |
| 0.015 | 0.215 | 0.066 | Argininosuccinate synthase inhibitor | 0.066 0.032 DBMET02979 | DBMET02979 | |
| 0.039 | 0.245 | 0.225 | GABA C receptor agonist | 0.225 0.016 DBMET02979 | DBMET02979 | |
| 0.053 | 0.263 | 0.101 | Glutamate (mGluR7) agonist | 0.101 0.058 DBMET02979 | DBMET02979 | |
| 0.019 | 0.231 | 0.07 | Aconitate hydratase inhibitor | 0.07 0.019 DBMET02979 | DBMET02979 | |
| 0.007 | 0.229 | 0.033 | Fumarate hydratase inhibitor | 0.033 0.025 DBMET02979 | DBMET02979 | |
| 0.018 | 0.244 | 0.084 | Catalase inhibitor | 0.084 0.045 DBMET02979 | DBMET02979 | |
| 0.027 | 0.258 | 0.089 | GABA aminotransferase inhibitor | 0.089 0.036 DBMET02979 | DBMET02979 | |
| 0.015 | 0.25 | 0.08 | Carbamoyl phosphate synthetase inhibitor | 0.08 0.029 DBMET02979 | DBMET02979 | |
| 0.103 | 0.35 | 0.132 | Heat shock protein 70 antagonist | 0.132 0.113 DBMET02979 | DBMET02979 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |